VR Adviser, LLC
- SEC CIK
- 0001615982
- Latest filing
- Aug 14, 2026
Holdings in Q2 2023
Holdings as of Jun 30, 2023, filed Aug 11, 2023. Long positions only; changes compare share counts with Q1 2023.
- Positions
- 30
- +5 vs. Q1 2023
- Portfolio value
- $625.4M
- +$113.2M (+22.1%) vs. Q1 2023
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| AVTXAvalo Therapeutics, Inc. | COM NEW | 1,250,000 | $444.0K | 0.1% | +250,000+25.0% | Added | History |
| Affimed N VN01045108 | COM | 1,428,571 | $854.6K | 0.1% | 00.0% | Unchanged | – |
| RLYBRallybio Corp | COM | 268,532 | $1.52M | 0.2% | 00.0% | Unchanged | History |
| BDTXBlack Diamond Therapeutics, Inc. | COM | 353,629 | $1.79M | 0.3% | +353,629 | New | History |
| SYRESpyre Therapeutics, Inc. | COM | 6,343,221 | $2.86M | 0.5% | +6,343,221 | New | History |
| LYRALyra Therapeutics, Inc. | COM | 924,170 | $3.80M | 0.6% | 00.0% | Unchanged | History |
| PLRXPliant Therapeutics, Inc. | COM | 288,949 | $5.24M | 0.8% | −1,141,051−79.8% | Reduced | History |
| PRAXPraxis Precision Medicines, Inc. | COM | 5,304,410 | $6.10M | 1.0% | +5,304,410 | New | History |
| ADVMAdverum Biotechnologies, Inc. | COM | 3,886,246 | $6.18M | 1.0% | +3,886,246 | New | History |
| MISTMilestone Pharmaceuticals Inc. | COM | 2,208,812 | $6.30M | 1.0% | 00.0% | Unchanged | History |
| THRXTheseus Pharmaceuticals, Inc. | COM | 770,000 | $7.18M | 1.1% | 00.0% | Unchanged | History |
| APLTApplied Therapeutics, Inc. | COM | 5,658,034 | $7.24M | 1.2% | +5,658,034 | New | History |
| TRVITrevi Therapeutics, Inc. | COM | 3,422,397 | $8.18M | 1.3% | +372,375+12.2% | Added | History |
| ACRSAclaris Therapeutics, Inc. | COM | 1,040,754 | $10.8M | 1.7% | 00.0% | Unchanged | History |
| ORICOric Pharmaceuticals, Inc. | COM | 2,142,856 | $16.6M | 2.7% | +2,142,856 | New | History |
| RYTMRhythm Pharmaceuticals, Inc. | COM | 1,090,000 | $18.0M | 2.9% | +1,090,000 | New | History |
| PHVSPharvaris N.V. | COM | 1,326,200 | $20.1M | 3.2% | +1,326,200 | New | History |
| SVRASavara Inc | COM | 6,351,531 | $20.3M | 3.2% | 00.0% | Unchanged | History |
| CELCCelcuity Inc. | COM | 2,105,386 | $23.1M | 3.7% | 00.0% | Unchanged | History |
| DYNDyne Therapeutics, Inc. | COM | 2,173,913 | $24.5M | 3.9% | +2,173,913 | New | History |
| CABACabaletta Bio, Inc. | COM | 1,973,251 | $25.5M | 4.1% | 00.0% | Unchanged | History |
| TERNTerns Pharmaceuticals, Inc. | COM | 2,972,869 | $26.0M | 4.2% | −646,653−17.9% | Reduced | History |
| KALVKalVista Pharmaceuticals, Inc. | COM | 2,916,667 | $26.3M | 4.2% | 00.0% | Unchanged | History |
| AMAMAmbrx Biopharma Cayman, Inc. | SPONSORED ADS | 2,484,960 | $40.9M | 6.5% | −813,617−24.7% | Reduced | History |
| GHRSGH Research PLC | ORDINARY SHARES | 3,517,125 | $41.7M | 6.7% | 00.0% | Unchanged | History |
| MRUSMerus N.V. | COM | 1,726,214 | $45.5M | 7.3% | +500,000+40.8% | Added | History |
| ELVNEnliven Therapeutics, Inc. | COM | 2,230,127 | $45.5M | 7.3% | +15,985+0.7% | Added | History |
| FDMT4D Molecular Therapeutics, Inc. | COM | 3,000,000 | $54.2M | 8.7% | +3,000,000 | New | History |
| COGTCogent Biosciences, Inc. | COM | 4,684,132 | $55.5M | 8.9% | −200,845−4.1% | Reduced | History |
| VRDNViridian Therapeutics, Inc. | COM | 3,082,622 | $73.3M | 11.7% | +382,757+14.2% | Added | History |
Sold out since Q1 2023 (5)
Positions held at the end of Q1 2023 that are gone from this filing.
| Security | Class | Shares in Q1 2023 | Value in Q1 2023 | % of portfolio in Q1 2023 | History |
|---|---|---|---|---|---|
| DICEDICE Therapeutics, Inc. | COM | 819,000 | $23.5M | 4.6% | History |
| JBIOJade Biosciences, Inc. | COM | 833,927 | $16.8M | 3.3% | History |
| Vectivbio Hldg AGH9060V101 | ORD SHS | 1,866,000 | $15.9M | 3.1% | – |
| ANNXAnnexon, Inc. | COM | 3,220,050 | $12.4M | 2.4% | History |
| FULCFulcrum Therapeutics, Inc. | COM | 1,307,094 | $3.73M | 0.7% | History |